Ocrelizumab and Pregnancy: A New Era for MS Treatment?
The evolving landscape of multiple sclerosis (MS) treatment during pregnancy is witnessing significant advancements. At the American Academy of Neurology (AAN) 2025 Annual Meeting, Genentech presented data on the potential safety of ocrelizumab during and after pregnancy. This could mark a substantial shift in the treatment paradigm for women with MS, balancing disease management with family planning.
Understanding Ocrelizumab’s Role in Pregnancy
Ocrelizumab (Ocrevus) is an anti-CD20 monoclonal antibody, effective in reducing the frequency of relapses in MS patients. Historically, concerns have surrounded its use during pregnancy due to potential risks to the fetus. Key opinion leaders previously advised women planning to conceive to switch to milder disease-modifying therapies (DMTs) like teriflunomide and fumarate. However, emerging research from the MINORE and SOPRANINO studies is challenging this status quo.
These studies are investigating the transfer of ocrelizumab through the placenta and breastmilk, indicating that resumed usage post-pregnancy may not pose significant risks to infants. Genentech’s findings have led to a significant reduction in the required contraceptive window post-treatment. European summaries of product characteristics now reflect a change: four months instead of twelve after the last dose.
Implications for Other Anti-CD20 Therapies
The impactful outcomes from Genentech’s studies also extend to other anti-CD20 monoclonal antibodies like Novartis’ Kesimpta and TG Therapeutics’ Briumvi, which share similar mechanisms of action. This could streamline treatment options for MS patients, providing more flexibility in family planning. The shorter contraception timeframe for ocrelizumab could soon become a standard for its counterparts, with adjustments based on pharmacokinetic data.
Pro tip: Always consult with your healthcare provider before making any treatment changes, especially concerning new clinical data and recommendations.
Modern Management of MS During Breastfeeding
Breastfeeding while managing MS introduces another layer of complexity, given the possibility of monoclonal antibodies passing into breastmilk. However, optimistic data from the SAPORINO study suggests breastfeeding can safely resume with ocrelizumab therapy. Novartis and TG Therapeutics are similarly exploring this with their respective Phase IV trials (KATHAROS and PROVIDE) to confirm safety parallels.
These studies are pivotal in determining whether infants exposed to these antibodies develop any unsatisfactory humoral immune responses post-vaccination, a critical aspect yet to be fully understood.
The Future of MS Treatment: A Paradigm Shift?
If ongoing studies reaffirm the safety of resuming ocrelizumab post-breastfeeding without significant adverse effects, it could revolutionize MS treatment approaches, making the process of managing the disease less restrictive during pregnancy and breastfeeding. This could lead to revisions in treatment guidelines for all anti-CD20 medications.
Did you know? The ability to continue effective MS treatment during pregnancy and breastfeeding can significantly improve the quality of life and disease outcomes for many women with MS.
FAQs on MS Treatment with Ocrelizumab During Pregnancy
Q: Can women with MS take ocrelizumab during pregnancy?
A: Current studies suggest it’s safe, but decisions should always be made in consultation with healthcare providers.
Q: Is breastfeeding possible while on ocrelizumab?
A: Recent findings indicate it is, though further studies are ongoing to ensure long-term safety.
Call to Action
Stay informed about the evolving treatments for MS and how they might impact your family planning. Subscribe to our newsletter for the latest updates, expert insights, and more.
This article synthesizes current knowledge and future trends concerning MS treatment with ocrelizumab during pregnancy, structured to engage readers and optimize for search engines while being accessible and informative.
Worth a look